Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells

Journal of Clinical Investigation

Volumn 111, Issue 5, 2003, Pages 639-647

  Molldrem, Jeffrey J ^a   Lee, Peter P ^b   Kant, Shreya ^a   Wieder, Eric ^a   Jiang, Weidong ^a   Lu, Sijie ^a   Wang, Changqing ^a   Davis, Mark M ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; INTERFERON; MYELOBLASTIN; PROTEIN PR1; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MYELOBLASTIN; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037370364     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200316398     Document Type: Article

References (38)

1. Hui, K., Grosveld, F., and Festenstein, H. 1984. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature. 311:750-752.
2. Kaklamanis, L., et al. 1992. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int. J. Cancer. 51:379-385.
3. Restifo, N.P., et al. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265-272.
4. Maeurer, M.J., et al. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 98:1633-1641.
5. Matulonis, U.A., et. al. 1995. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 85:2507-2515.
6. Munro, J.M. 1994. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood. 83:793-798.
7. Richter, G., et al. 1993. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53:4134-4137.
8. Bogen, B. 1996. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26:2671-2679.
9. Speiser, D.E., et al. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
10. Staveley-O'Carroll, K., et al. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U. S. A. 95:1178-1183.
11. Lee, P.P., et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
12. Pardoll, D.M. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:227-238.
13. Altman, J.D., et al. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-96.
14. Molldrem, J.J., 2000. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6:1018-1023.
15. Molldrem, J., et al. 1996. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 88:2450-2457.
16. Molldrem, J.J., et al. 1997. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 90:2529-2534.
17. Scheibenbogen, C., et al. 2002. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 100:2132-2137.
18. Molldrem, J.J., Lee, P.P., Wang, C., Champlin, R.E., and Davis, M.M. 1999. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:2675-2681.
19. Savage, P.A., Boniface, J.J., and Davis, M.M. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity. 10:485-492.
20. Yee, C., Savage, P.A., Lee, P.P., Davis, M.M., and Greenberg, P.D. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162:2227-2234.
21. Alexander-Miller, M.A., Derby, M.A., Sarin, A., Henkart, P.A., and Berzofsky, J.A. 1998. Supraoptimal peptide-major histocompatibility complex causes a decrease in bcl-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 188:1391-1399.
22. Alexander-Miller, M.A., Leggatt, G.R., and Berzofsky, J.A. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 93:4102-4107.
23. Zeh, H.J., 3rd, Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A., and Yang, J.C. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989-994.
24. Rees, W., et al. 1999. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 96:9781-9786.
25. Anderton, S.M., Radu, C.G., Lowrey, P.A., Ward, E.S., and Wraith, D.C. 2001. Negative selection during the peripheral immune response to antigen. J. Exp. Med. 193:1-11.
26. Grossman, Z., and Paul, W.E. 1992. Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses. Proc. Natl. Acad. Sci. U. S. A. 89:10365-10369.
27. Alam, S.M., et al. 1996. T-cell-receptor affinity and thymocyte positive selection. Nature. 381:616-620.
28. Rubio-Godoy, V., et al. 2001. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc. Natl. Acad. Sci. U. S. A. 98:10302-10307.
29. Echchakir, H., et al. 2002. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl. Acad. Sci. U. S. A. 99:9358-9363.
30. Bullock, T.N., Mullins, D.W., Colella, T.A., and Engelhard, V.H. 2001. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J. Immunol. 167:5824-5831.
31. Rosenberg, S.A., et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
32. Nestle, F.O., et al. 1998. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
33. Dyall, R., et al. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553-1561.
34. Gallimore, A., et al. 1998. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187:1383-1393.
35. Williams, R.C., et al. 1994. Epitopes on proteinase 3 recognized by antibodies from patients with Wegener's granulomatosis. J. Immunol. 152:4722-4732.
36. Ballieux, B.E., et al. 1995. Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin. Exp. Immunol. 100:186-193.
37. Colella, T.A., et al. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191:1221-1232.
38. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.